248 related articles for article (PubMed ID: 34314671)
1. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
Li S; Gibbs I
J Pharm Pharm Sci; 2021; 24():381-389. PubMed ID: 34314671
[TBL] [Abstract][Full Text] [Related]
2. Medical Marketing in the United States, 1997-2016.
Schwartz LM; Woloshin S
JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
[TBL] [Abstract][Full Text] [Related]
3. The federal regulation of prescription drug advertising and promotion.
Kessler DA; Pines WL
JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
[TBL] [Abstract][Full Text] [Related]
4. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
5. A decade of direct-to-consumer advertising of prescription drugs.
Donohue JM; Cevasco M; Rosenthal MB
N Engl J Med; 2007 Aug; 357(7):673-81. PubMed ID: 17699817
[TBL] [Abstract][Full Text] [Related]
6. Regulation of prescription drug promotion: direct-to-consumer advertising.
Baylor-Henry M; Drezin NA
Clin Ther; 1998; 20 Suppl C():C86-95. PubMed ID: 9915094
[TBL] [Abstract][Full Text] [Related]
7. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
Zagrodney KAP; Sheikhan NY; Pinto A; Sheikhan T; Witek TJ
Pharmaceut Med; 2021 Jan; 35(1):31-38. PubMed ID: 33453042
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
Vilhelmsson A; Davis C; Mulinari S
PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
[TBL] [Abstract][Full Text] [Related]
9. Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.
Nguyen D; Seoane-Vazquez E; Rodriguez-Monguio R; Montagne M
BMC Health Serv Res; 2013 Jan; 13():27. PubMed ID: 23339419
[TBL] [Abstract][Full Text] [Related]
10. Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999.
Palmer JA; Timm AR; Neumann PJ
J Manag Care Pharm; 2008 Oct; 14(8):749-55. PubMed ID: 18983204
[TBL] [Abstract][Full Text] [Related]
11. Evaluating promotional claims as false or misleading.
Brushwood DB; Knox CA; Liu W; Jenkins KA
Am J Health Syst Pharm; 2013 Nov; 70(21):1941-4. PubMed ID: 24128969
[TBL] [Abstract][Full Text] [Related]
12. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
Cowden AL; Katz KA
Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
[TBL] [Abstract][Full Text] [Related]
13. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
14. Promotion of prescription drugs to consumers.
Rosenthal MB; Berndt ER; Donohue JM; Frank RG; Epstein AM
N Engl J Med; 2002 Feb; 346(7):498-505. PubMed ID: 11844852
[TBL] [Abstract][Full Text] [Related]
15. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
Greenwood K
Am J Law Med; 2011; 37(2-3):278-98. PubMed ID: 21847882
[TBL] [Abstract][Full Text] [Related]
16. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
Bagley CE; Mitts J; Tinsley RJ
Cornell J Law Public Policy; 2013; 23(2):337-93. PubMed ID: 25330567
[TBL] [Abstract][Full Text] [Related]
17. United States v. Caronia: The increasing strength of commercial free speech and potential new emphasis on classifying off-label promotion as "false and misleading".
Scheineson MJ; Cuevas G
Food Drug Law J; 2013; 68(2):201-16, iii. PubMed ID: 24640469
[TBL] [Abstract][Full Text] [Related]
18. Prescription drug advertising: is it a driving force on drug pricing?
Millstein LG
N C Med J; 2003; 64(6):289-91. PubMed ID: 14983621
[TBL] [Abstract][Full Text] [Related]
19. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
20. The US Opioid Crisis: Current Federal and State Legal Issues.
Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
